Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: transcending to a Friday close

February 22, 2019 8:47am

As the Advance/Decline Line (A/DL) exhibited Thursday with a minor gap with 21/22 and 1 flat)

Warmer climates (86) do make the cold (39) go far away – it’s my “bones” that were suffering

News: Voyager Therapeutics (VYGR) and AbbVie (ABBV), a global biopharmaceutical company, today announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases (synucleinopathies) characterized by the abnormal accumulation of misfolded alpha-synuclein protein.

Quarterly results: bluebird Bio Inc. (BLUE) on Thursday reported a Q4 loss of $149 or -$2.72 per share beat “street” expectations for a loss of $2.83 per share. BioMarin Pharmaceutical (BMRN) reported a Q4 loss of $3.7 M or -$0.03 per share. Losses, adjusted for one-time gains and costs, were -$0.06 per share. The results missed “street” expectations for earnings of $0.10 per share.

Pre-open indications: 3 BUY, 1 SELL and 1 TRADE

Presenting alternative hypotheses clarifies material facts and evidence available to investors. “Devil’s Advocacy” also provides greater confidence that the current sector outlook will hold-up to close scrutiny!

U.S. stock index futures are in the green

Dow futures are UP +0.47% (+122 points), S&P futures are UP 0.41% (+11.25 points) and NASDAQ futures are UP +0.49% (+35 points)

U.S. stock futures were higher on the final trading day of the week, optimism has risen over the chances of both countries securing a deal to end their protracted trade war, but some experts say the most difficult part is yet to come as high level talks continue into Friday.

European markets edge higher as US-China trade talks continued;

Most major Asian stock markets advanced;

Data docket: December durable goods orders rose 1.2% <Commerce Department>. The department also said core capital goods orders fell 0.7 percent while economists polled by Reuters expected a gain of 0.2%.The Philadelphia Federal Reserve business index fell to negative 4.1 in February — its lowest level since May 2016 — from 17 in January. Economists polled by Dow Jones expected a print of 14.

Friday’s indications in the pre-market:

The iShares Nasdaq Biotechnology (IBB) is NOT indicating

The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +0.74% UPSIDE

The Health Care Select Sector SPDR ETF (XLV) is NOT indicating

The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.62% UPSIDE

Henry’omics:

No post last night, plane was late and warmer climate lulled me into a different mode or was it the cocktails or two or was it three?

3 out of the 21 upside had higher (than the 3 month average) volume
4 out of the 22 downside experienced greater volume (than the 3 month average)

Quarterly results:

bluebird Bio Inc. (BLUE) on Thursday reported a Q4 loss of $149 or -$2.72 per share beat “street” expectations for a loss of $2.83 per share. BLUE posted revenue of $19.2 M, also topping forecasts of the expected $9.8 M. For FY18, BLYE reported that its loss widened to $555.6 M, or $10.68 per share. Revenue was reported as $54.6 M. Shares have climbed 28% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $127.24, a decline of 39% in the last 12 months.

BioMarin Pharmaceutical (BMRN) reported a Q4 loss of $3.7 M or -$0.03 per share. Losses, adjusted for one-time gains and costs, were -$0.06 per share. The results missed “street” expectations for earnings of $0.10 per share. BMRN posted revenue of $353.2 M, which also missed forecasts of the expected $379.7 M. For the year, BMRN reported that its loss narrowed to $77.2 M, or -$0.44 cents per share. Revenue was reported as $1.49 B.

Companies in my headlights – It’s your decision; I provide an idea and context:

bluebird Bio (BLUE) closed down -$6.20 to $127.24 after a BEAT on “earnings” – losses were still there but, forecasts were beat. There is a positive +$0.32 or +0.25% aftermarket indication – BUY;

Sangamo Therapeutics (SGMO) closed up +$0.08 to $8.54 after Wednesday’s-$0.26 to $8.46 after Tuesday’s -$0.07 to $8.72. The FDA accepted an IND application for ST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease. Current standard of care for this rare, progressive condition involves regular lifelong infusions of enzyme replacement therapy (ERT) – Maintaining BUY;

Mesoblast (MESO) closed was down -$0.07 to $4.19 after Wednesday’s +$0.06 to $4.26 after Tuesday’s-$0.05 to $4.20 and reports yesterday. The P3 has enrolled but will the debt levels increase as the quarterly results get unveiled. MESO reported Q2 net loss of -$24.6 M or -$5.00 per share and 1st half “numbers - $77 M in cash ($15 M of debt financing), revenue of $13.5 M with an R&D increase of $2.4 M and SG&A with a $5.1 M financing cost – Maintaining SELL;

Voyager Therapeutics (VYGR) closed and AbbVie (ABBV), a global biopharmaceutical company, today announced an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s disease and other diseases (synucleinopathies) characterized by the abnormal accumulation of misfolded alpha-synuclein protein. VYGR is UP +$1.71 or +16.01% - BUY;

Ultragenyx Pharmaceuticals (RARE) closed up +$3.72 to $60.51 after Tuesday’s +$0.16 to $56.81; RARE reported a Q4 loss of $87.8 M or a per share loss of -$1.73. The results surpassed “street” expectations. The average estimate was for a loss of $1.74 per share. RARE posted revenue of $16.3 million in the period, also surpassing the “forecast” of $13.3 million. Ultragenyx shares have climbed 31% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $56.81, a climb of 21% in the last 12 months. It is getting RICH having opened January 2^nd at $ 41.72 – I’d take a little OFF the table but, maintaining a position - TRADE;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.